PsyBio Therapeutics Inc

PsyBio Therapeutics Inc Pioneering The Next Generation Of Targeted Psychoactive Medications
TSXV: OTCQB:

PsyBio

The Company has a collaboration with Miami University, Oxford Ohio where they have filed intellectual property for biosynthesized psilocybin, it’s intermediates, and other molecules. With a proprietary platform technology, the Company is in the process of developing new drugs by producing novel psychoactive molecules from genetically modified bacteria. The platform is expected to enable the rapid generation of highly stable compounds far cheaper, faster and greener than any other published method. Currently working in the laboratory on over twenty psychedelically inspired compounds from different fungi and plants with unique psychoactive properties. PsyBio is in the process of preparing the initial molecules for clinical batch manufacturing and concurrently preparing an investigational new drug (“IND”) application to study the compounds in patients with cancer related depression.

Address

4400 Sample Road, Suite 138
Coconut Creek, FL
33073

Telephone

+12032280123

Website

Alerts

Be the first to know and let us send you an email when PsyBio Therapeutics Inc posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category

PsyBio Therapeutics Inc

PsyBio Therapeutics (“PsyBio” or the “Company”) is a biotechnology company developing a portfolio of psychoactive compounds targeted for the treatment of mental health challenges and other disorders.

​The Company has a collaboration with Miami University, Oxford Ohio where they have filed intellectual property for biosynthesized psilocybin, it’s intermediates, and other molecules.

With a proprietary platform technology, the Company is in the process of developing new drugs by producing novel psychoactive molecules from genetically modified bacteria. The platform is expected to enable the rapid generation of highly stable compounds far cheaper, faster and greener than any other published method.

Currently working in the laboratory on over twenty psychedelically inspired compounds from different fungi and plants with unique psychoactive properties.